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The Food and Drug Administration (FDA) issued a public
health advisory regarding the use
of
benzocaine
spray
(Hurricaine®, Topex®, Cetacaine®) on February 10, 2006.1
Benzocaine spray is a local anesthetic used to numb the mouth
and throat during minor surgical
procedures such as endoscopy
and bronchoscopy.1,2
When
used appropriately, benzocaine
may occasionally cause methemoglobinemia.1,2 Methemoglobinemia has also resulted due to
medication errors and using benzocaine for a longer duration or
in a higher dose than is recommended.1
Methemoglobinemia occurs due
to either increased methemoglobin production or decreased
methemoglobin
reduction.3,4
Methemoglobin is a form of hemoglobin in which the ferrous
irons of heme have been oxidized to the ferric state.3,4
Methemoglobin is unable to bind
oxygen.3,4 In methemoglobinemia, the oxygen affinity of ferrous heme in the hemoglobin
tetramer is increased, resulting in
a “left-shifted” oxygen dissociation curve and impaired oxygen

delivery to the tissues.3,4 As a result, patients with increased concentrations of methemoglobin
have a functional anemia.3,4
The FDA advisory states that
practitioners should consider several things when using benzocaine
spray during procedures requiring
tube placement in the larynx or
pharynx. First, benzocaine spray
can result in dangerous concentrations of methemoglobin. Up to
35% of benzocaine applied to mucous membranes is absorbed sysAbsorption is intemically.1
creased when the product is applied to inflamed tissue. Secondly, patients with asthma, bronchitis, chronic obstructive pulmonary disease (COPD), heart disease, or those who smoke have an
increased risk of complications if
they develop methemoglobinemia
and may benefit from alternative
therapeutic agents.
There are
also certain patients who have an
increased risk of developing
These
methemoglobinemia.1,3,4
patients include infants; patients
with hemoglobin M disease; and
patients with deficiencies in glucose-6-phosphate dehydrogenase
(G6PD), NADH-methemoglobin
reductase, and pyruvate kinase.1,3,4
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Lidocaine is a reasonable alternative for both patient groups.
FDA recommends that practitioners use the minimum amount of
benzocaine needed to reduce the
risk of methemoglobinemia. According to the product labeling,
the recommended dose of Hurricaine® spray is 1 spray in a lessthan-1-second burst. For Cetacaine®, sprays in excess of 2 seconds are contraindicated. Topex®
is typically administered in 2 to 3
metered sprays, and the maximum
dose is 5 sprays.
Patients who receive benzocaine
spray should be carefully monitored for signs of methemoglobinemia including pale gray- or
blue-colored skin, headache, lightheadedness, shortness of breath,
anxiety, fatigue, and/or tachycardia. FDA cautions practitioners
that methemoglobinemia makes
pulse oximetry unreliable. Methemoglobin concentrations should
be measured using a cooximeter.1,3
Patients who are
thought to have high concentrations of methemoglobin should be
treated promptly.
Additional information may be
found at: www.fda.gov/cder/ drug/
advisory/benzocaine.htm.

Automatic Therapeutic
Substitution:
Angiotensin Converting
Enzyme Inhibitors
By
Krystal Moorman, PharmD

Effective March 15, 2006, angiotensin converting enzyme inhibitors (ACEIs) will be included in

Table 1: Oral ACE-inhibitor Dosing Conversion
Order Written As
Converted To
Benazepril 5 mg, Daily
Lisinopril 5 mg, Daily
Benazepril 10 mg, Daily
Lisinopril 10 mg, Daily
Benazepril 20 mg, Daily
Lisinopril 20 mg, Daily
Benazepril 40 mg, Daily
Lisinopril 40 mg, Daily
Enalapril 5 mg, Daily
Lisinopril 5 mg, Daily
Enalapril 10 mg, Daily
Lisinopril 10 mg, Daily
Enalapril 20 mg, Daily
Lisinopril 20 mg, Daily
Enalapril 40 mg, Daily
Lisinopril 40 mg, Daily
Fosinopril 5 mg, Daily
Lisinopril 5 mg, Daily
Fosinopril 10 mg, Daily
Lisinopril 10 mg, Daily
Fosinopril 20 mg, Daily
Lisinopril 20 mg, Daily
Fosinopril 40 mg, Daily
Lisinopril 40 mg, Daily
Moexipril 3.75 mg, Daily
Lisinopril 5 mg, Daily
Moexipril 7.5 mg, Daily
Lisinopril 10 mg, Daily
Moexipril 15 mg, Daily
Lisinopril 20 mg, Daily
Moexipril 30 mg, Daily
Lisinopril 40 mg, Daily
Perindopril 2 mg, Daily
Lisinopril 5 mg, Daily
Perindopril 4 mg, Daily
Lisinopril 10 mg, Daily
Perindopril 8 mg, Daily
Lisinopril 20 mg, Daily
Perindopril 16 mg, Daily
Lisinopril 40 mg, Daily
Quinapril 5 mg, Daily
Lisinopril 5 mg, Daily
Quinapril 10 mg, Daily
Lisinopril 10 mg, Daily
Quinapril 20 mg, Daily
Lisinopril 20 mg, Daily
Quinapril 40 mg, Daily
Lisinopril 40 mg, Daily
Ramipril 1.25 mg, Daily
Lisinopril 5 mg, Daily
Ramipril 2.5 mg, Daily
Lisinopril 10 mg, Daily
Ramipril 5 mg, Daily
Lisinopril 20 mg, Daily
Ramipril 10 mg, Daily
Lisinopril 40 mg, Daily
Ramipril 20 mg, Daily
Lisinopril 40 mg, Daily
Trandolapril 1 mg, Daily
Lisinopril 5 mg, Daily
Trandolapril 2 mg, Daily
Lisinopril 10 mg, Daily
Trandolapril 4 mg, Daily
Lisinopril 20 mg, Daily
Trandolapril 8 mg, Daily
Lisinopril 40 mg, Daily

the automatic therapeutic substitution (ATS) program. The protocol specifies that orders written for benazepril, enalapril, fosinopril, moexipril, perindopril,
quinapril, ramipril, and trandolapril will be converted to lisinopril (Table 1). Captopril and
enalaprilat are excluded from
this ATS. This ATS is applicable to adult inpatients. If a physician does not want a patient to
receive lisinopril, he/she must
write the order for the desired
ACEI, include “dispense as written” in the order, and provide
appropriate clinical justification.

Therapeutic Alternative
to Cefotetan
AstraZeneca announced that it
would discontinue production of
cefotetan in February 2005.
Therefore, the Anti-infective
Subcommittee has made the following recommendation regarding alternative therapy for patients undergoing abdominal surgery: cefazolin 1 to 2 g in combination with metronidazole 500
mg, administered intravenously.
If you need additional information, please contact the Drug Information Center at 2-3896.
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Gatifloxacin is
Contraindicated in
Patients with Diabetes

Acute sinusitis: Augmentin®
875 mg, administered orally,
twice daily.

By
Krystal Moorman, PharmD

Community acquired pneumonia:
Previously healthy patients being treated as outpatients–
azithromycin 500 mg, administered orally, once, then 250 mg,
administered orally, daily in
combination with amoxicillin
1 g, administered orally, 3 times
daily.

Bristol-Myers Squibb (BMS) announced changes to the prescribing information for gatifloxacin
(Tequin®). The changes include
an updating of the existing warning on hypo- and hyperglycemia
and a contraindication for use in
patients with diabetes. The
changes also include information
identifying other risk factors for
developing hypo- or hyperglycemia including advanced age, renal
insufficiency, and concomitant
use of glucose-altering medications. Additional information is
posted at www.fda.gov/
medwatch/safety/2006/
tequin_DHCP.pdf.
Listed below are formulary alternatives to gatifloxacin for patients
with diabetes. Clinicians should
consider patient- and pathogen
characteristics when choosing an
alternative. These recommendations apply to situations in which
gatifloxacin would be an appropriate therapeutic choice—not necessarily first-line treatment for a particular disease state.
Acute bacterial exacerbation of
chronic bronchitis: Augmentin®
875 mg, administered orally,
twice daily; Unasyn® 1.5 to 3 g,
administered intravenously, every
6 hours; cefuroxime 750 mg to 1.5
g, administered intravenously,
every 8 hours; cefotaxime 1 g, administered intravenously, every 8
to 12 hours; ceftriaxone 1 g, administered intravenously, daily.

Patients with comorbidities who
have not recently received antibiotics and are being treated as
outpatients – azithromycin
500 mg, administered orally,
once, then 250 mg, administered
orally, daily.
Patients with comorbidities who
have recently received antibiotics – cefpodoxime 200 mg, administered orally, every 12 hours
or amoxicillin 1 g, administered
orally, 3 times daily.
Non-ICU patients — ceftriaxone
1 g, administered intravenously,
daily with azithromycin 500 mg,
administered intravenously,
daily.
ICU patients – ceftriaxone
2 g, administered intravenously,
daily with azithromycin 500 mg,
administered intravenously,
daily.
Uncomplicated cystitis: Fluoroquinolones are only recommended if the local E. coli resistance to Septra® is at least 20%.
In these cases, it is necessary to
substitute a nonformulary fluoroquinolone (FQ). Moxifloxacin
should not be used to treat uri-

nary tract infections due to inadequate urine concentration.
Complicated urinary tract infections: Zosyn® 3.375 g, administered intravenously, every 6 hours;
ampicillin 500 mg, administered
intravenously, every 6 hours in
combination with gentamicin.
Pyelonephritis:
Outpatient treatment—
Augmentin® 875 mg, administered orally, twice daily; Septra®
DS, administered orally, twice
daily.
Hospital treatment — ampicillin
500 mg, administered intravenously, every 6 hours in combination with gentamicin; ceftazidime
2 g, administered intravenously,
every 8 hours; Zosyn® 3.375 g
administered intravenously, every
6 hours; Unasyn® 3 g, administered intravenously, every 6 hours.
Patients should be treated for
14 days.
Uncomplicated urethral and
cervical gonorrhea or acute, uncomplicated rectal infection in
women due to Neisseria gonorrheae: ceftriaxone 125 mg, administered intramuscularly, once
or cefpodoxime 400 mg, administered orally, once in combination
with azithromycin 1 g, administered orally, once or doxycycline
100 mg, administered orally,
twice daily, for 7 days.
Patients who require FQ therapy
may be treated with levofloxacin
or moxifloxacin. For further assistance selecting an antibiotic
regimen, please contact the pharmacist in your area or the Drug
Information Center at 2-3896.
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MED•U•WAY
Conference to Focus on
the Role of Percent
Carbohydrate-deficient
Transferrin Screening
for Heavy Alcohol Use
The next MED•U•WAY will
focus on percent carbohydratedeficient transferrin (CDT)
screening for heavy alcohol use.
The program will be held on
Thursday, April 20, 2006, at
12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Karen Stanley, APRN, BC, Psychiatric Consultation Liaison
Nurse; Raymond Anton, MD, Distinguished University Professor of
Psychiatry and Director for the
Center of Drug and Alcohol Programs; Peter Miller, PhD, Professor of Psychiatry; and Cynthia
Dominick, MHA, Manager of the
Clinical Neurobiology Laboratory.
Attendees will receive 1 credit
hour of continuing education.

Formulary Update
The Pharmacy and Therapeutics
Committee recently approved the
following formulary changes, effective March 15, 2006:

Changes in Restrictions:
Bevacizumab (Avastin®)
The restriction for bevacizumab
was revised to allow intravitreal
administration by an ophthalmologist on an individual basis
for patients experiencing treatment failure with photodynamic
therapy and pegaptanib. Patients
will be required to sign an informed consent prior to receiving this therapy. The formulary
effective date will be assigned
once the institutional review
board has approved the informed
consent and a mechanism for
reimbursement has been established.

0.9% sodium chloride with benzyl
alcohol injection
2.5-mL syringe

Automatic Therapeutic Substitution:
Orders written for benazepril,
enalapril, fosinopril, moexipril,
perindopril, quinapril, ramipril,
and trandolapril will be converted to lisinopril. This ATS
will be applicable to adult patients. Captopril and enalaprilat
are excluded from this ATS.

Masse Breast Cream®
cream [60 grams]

Line Extensions:
Nifedipine (various)
4-mg/mL extemporaneous oral
solution
Morphine (various)
0.2- and 1-mg/mL extemporaneous intravenous dilution

Additions with Restrictions:
Palonosetron (Aloxi®)
Prescribing will be restricted to
physicians on the hematology/oncology services for patients
who have failed therapy with ondansetron.

Lorazepam (various)
0.2-mg/mL extemporaneous
intravenous dilution

Dexmedetomidine (Precedex®)
Prescribing will be restricted for
use during awake craniotomies.

Deletions:
Salicylic acid (Keralyt®)
6% gel [30 grams]

Aripiprazole (Abilify®)
5-mg tablets

Lidocaine (various)
2.5% ointment
Metyrapone (various)
250-mg capsule
Prednisolone phosphate (various)
0.125% ES solution
Neomycin (various)
0.5% ointment [15 grams]
Barium sulfate (EZPaque®)
96% w/w suspension
Methybenzethonium (Diaparene®)
ointment [60 grams]

Humulin ultralente
(Humulin® U)
100 units/mL

insulin

Iothalamate meglumine
(Cysto-CONRAY® II)
500-mL bottle
Gadodiamide injection
(Omniscan®)
5-mL vial
Iodixanol (Visipaque®)
270-mg/mL [100- and 150-mL
vial]; 320-mg/mL [100-mL vial]
Iohexol (Omnipaque®)
180-, 240-, 300-, and 350-mg vials
Iopamidol (Isovue®)
370-mg vial
Didanosine (Videx®)
25-, 50-, 100-, 150-, and 200-mg
chewable tablets
Ramipril (Altace®)
1.25-, 2.5-, 5-, and 10-mg tablets

